DreaMed Diabetes wins CE Mark for insulin therapy management platform

DreaMed Diabetes has won CE Mark clearance for its Advisor Pro decision-support platform, designed to help healthcare professionals manage insulin therapy for their Type I diabetes patients.
The company’s cloud-based platform provides personalized insulin treatment plans by combining data from insulin pumps and continuous glucose monitors. Using machine learning techniques, the system analyzes all of the data it collects from connected devices to come up with an optimized insulin dosing treatment plan.
Get the full story at our sister site, Drug Delivery Business News.
The post DreaMed Diabetes wins CE Mark for insulin therapy management platform appeared first on MassDevice.

Source: Mass Device - February 15, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Regulatory/Compliance DreaMed Diabetes Glooko Source Type: news